Aug 2, 2013

Lift helps polio survivor, others get into pool

Linda Margritz retrieves her water aerobics dumbbells from June Saylor after lowering herself into Tanglewood's pool in their 
new lift Wednesday morning. 
Margritz joked that other residents
 call her Tigger, because she exercises by bouncing around the pool on her right leg.

Post Polio Litaff, Association A.C _APPLAC Mexico

Jul 28, 2013

“The Story of Polio is Truly an American Tale,” Said Oshinsky,


Post Polio Litaff, Association A.C _APPLAC Mexico


Suggested Reading:

Halstead, L.S. (ed.). Managing Post-Polio: A Guide to Living Well with Post-Polio Syndrome. Washington, DC: NRH Press, 1998.
Jubelt, B., Agre, J.C. Characteristics and manage- ment of postpolio syndrome. Journal of the American Medical Association, 2000, volume 284, pages 412-414.
Maynard F.M., Headley, J.L. (eds.). Handbook on the Late Effects of Poliomyelitis. St. Louis, Mo.: Gazette International Networking Institute, 1999.
Post Polio Information Package for Health Care Professionals. Toronto: Ontario March of Dimes, 2000.
Post-Polio Syndrome: Identifying Best Practices in Diagnosis and Care. White Plains, N.Y.: March of Dimes, 2001. [This report was the basis for the guidelines in this brochure and derives from a May 2000 International Conference on PPS, sponsored by the U.S. March of Dimes in collaboration with the Roosevelt Warm Springs Institute for Rehabilitation. The report and this brochure are available on-line at]

Steering Committee
Lewis P. Rowland, MD, (Chair), Department of Neurology, Columbia University College of Physicians and Surgeons, New York, N.Y. John R. Bach, MD, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, N.J.
Kristian Borg, MD, PhD, Head, Huddinge University Hospital, Stockholm, Sweden Neil R. Cashman, MD, Center for Research in Neuro-Degenerative Diseases, University of Toronto, Ontario, Canada
Marinos C. Dalakas, MD, Neuromuscular Disease Section, National Institute of Neurological Disorders & Stroke, Bethesda, Md. Elizabeth Dean, PhD, PT, School of Rehabilitation Sciences, University of British Columbia, Vancouver, BC, Canada
Lauro S. Halstead, MD, Post-Polio Program, National Rehabilitation Hospital, Washington, DC Joan L. Headley, MS, International Polio Network, Saint Louis, Mo. T. Jacob John, MD, Department of Clinical Virology, Christian Medical College, Vellore, Tamil Nadu, India Richard B. Johnston, Jr., MD, Department of Pediatrics, National Jewish Medical and Research Center, Denver, Colo. Rhoda Olkin, PhD, Department of Clinical Psychology, California School of Professional Psychology, Alameda, Calif. Susan L. Perlman, MD, Department of Neurology, University of California at Los Angeles, Los Angeles, Calif. Daria A. Trojan, MD, MSc, McGill University, Montreal Neurological Hospital, Quebec, Canada Barbara G. Vickrey, MD, MPH, Department of Neurology, University of California at Los Angeles, Los Angeles, Calif. William W. Wendling, Cleveland Municipal School District, Cleveland, Ohio
Acknowledgment: We thank Sandra Donahue, Science Writer, March of Dimes, for condensing Post-Polio Syndrome: Identifying Best Practices in Diagnosis and Care.
Questions? Call: 888-MODIMES Visit: To order additional copies of this pamphlet: Call: 1-800-367-6630 Or write: March of Dimes P.O. Box 1657 Wilkes-Barre, Pa .

Guidelinefor people who have had polio

Post-Polio Syndrome 
31-1523-01 3/01 © The March of Dimes Birth Defects Foundation 2001

Guidelines for People who have had Polio

Post-Polio syndrome (PPS) is a disorder of the neuromuscular system that affects many people who had poliomyelitis many years earlier. However, most people who had polio do not develop PPS. PPS usually develops 15 or more years after an acute polio virus infection that resulted in some degree of temporary or permanent paralysis. The new problems arise after many years of stable muscle function. All told, as many as 250,000 U.S. polio survivors may have PPS.

What are the symptoms of PPS?

The main symptom of PPS is new muscle weakness that gradually worsens. It is often accompanied by decreased muscle endurance during activities, muscle and joint pain, muscle wasting and severe fatigue. These problems usually come on gradually, but may start suddenly if you have undergone surgery, or been hospitalized or confined to bed. Even muscles that were believed to be unaffected by the previous bout with polio may be affected. Less frequently, breathing difficulties and swallowing problems may occur. If these problems persist for at least one year, you may have PPS.
However, even if you have one or more of these symptoms, you may not have PPS. A complete med- ical evaluation may show that you have arthritis, tendonitis or cartilage damage, all of which can occur in the aging process, but are more common when move- ment and weight-bearing have been altered by the effects of weakened muscles. Various other conditions also cause progressive muscle weakness or fatigue.
If you think you might have PPS, you should consult your physician, who may refer you to a neurologist or other specialist, preferably one having experience with PPS. In addition to the neurological examination, doctors often recommend tests, such as imaging studies (computerized tomography and magnetic resonance imaging), to rule out other disorders with similar symptoms; however, there is no definite test for PPS. Continuing care, if indicated, is usually supervised by a neurologist or specialist in rehabilitative medicine.

What causes PPS?
The causes of PPS are not thoroughly understood. Many researchers believe that PPS symptoms result, at least in part, from the unusual stress placed on surviving nerve cells. During the initial attack of polio, some of the nerve cells in the spinal cord that control muscles (called motor neurons) are damaged or destroyed. Without impulses from these nerve cells, a muscle cannot function. Fortunately, some motor neurons usually survive the polio attack and send out new nerve connections to the orphaned muscle cells in an attempt to take over the function of the nerve cells that were destroyed. This process enables an individual to regain at least some use of affected muscles. However, after many years, the overburdened nerve cells may begin to fail, resulting in new muscle weakness.
Some research suggests that the normal aging process may also play a role. After the age of 60, most people have a decrease in the number of motor neurons in their spinal cords. Persons who have not had polio can lose a considerable number of motor neurons as they age without experiencing any serious muscle weakness. However, among polio survivors who already have lost a considerable number of motor neurons, this age-related loss may contribute to new muscle weakness. Both overuse and underuse of muscles may also contribute to muscle weakness.

How is PPS treated?
While there is no specific treatment for PPS, post- polio experts can help you develop a management plan that should lessen or eliminate some of your symptoms. To date, no medication has proven help- ful in reducing the muscle weakness and fatigue associated with PPS.
Most people with PPS can benefit from some form of exercise. An appropriate, non-fatiguing exercise program may help improve muscle strength and functioning. Fatigue is best treated with lifestyle changes, including regular rest periods and daytime naps. If you have muscle fatigue limited to specific muscle groups, you should pace yourself carefully,
interspersing bouts of physical activity with rest periods. Some individuals may benefit from weight loss. Assistive devices, such as braces and intermittent use of wheel chairs or motorized scooters for long distances also can help conserve energy. These lifestyle changes may also help ease muscle and joint pain, as can use of moist heat, ice, massage, and when necessary, medications.
Individuals with breathing problems may benefit from nighttime breathing assistance to help improve sleep and energy levels. Instruction on special swallowing techniques and diet alter- ations can make eating easier and safer for those with swallowing problems.

What research is needed on PPS?
An international steering committee made up of leading PPS researchers, convened by the March of Dimes, recommends additional research on the causes, symptoms, prevalence, diagnosis and treatment of PPS—with the goals of improving diagnosis and treatment of the disorder. For example, studies that provide more information on the typical course of symp- toms in PPS should help distinguish the disorder from other conditions that may have similar symptoms, and thereby improve diagnosis of PPS. A thorough evaluation of current manage- ment approaches used to lessen PPS symptoms should help identify the approaches that are most beneficial, and so lead to more effective treatment. Drug treatment also may benefit some PPS individuals, but more studies are needed to evaluate the effectiveness of several potential drug treatments. In order to improve patient care, the committee also recommends creation of regional centers or networks of providers with expertise in all aspects of PPS
For additional information: International Polio Network 4207 Lindell Blvd., #10 Saint Louis Mo. 63108-2915

Susan Perlman, MD Symptomatic Medication For PPS

By: Susan Perlman, M.D.
University of California, Los Angeles (UCLA)

Susan Perlman, M.D. is Associate Clinical Professor of Post-Polio Clinic at UCLA. Since 1988, the clinic has evaluated and treated 600 polio survivors, with an approach combining neurological assessment, neurorehabilitation techniques, medication, intervention and consultation with associates in orthopedics, medicine, sleep disorders, psychology and alternative (complementary) medicine. The clinic coordinates the dedicated support groups in Southern California and offers educational outreach to the health care community
POST-POLIO SYNDROME is a constellation of new symptoms (fatigue, weakness, pain, cold intolerance, muscle atrophy, or new problems with activities of daily living), occurring in survivors of definitively (by history, exam or electrical studies) proven acute poliomyelitis, after a period of at least 15 years of stable recovery and performance, and in the absence of any other medical or neurological condition. It is felt to result from the weakening and loss of previously recovered lower motor neuron connections to muscle, possibly due to aging, greater fragility of the recovered nerves, or immune system dysregulation. Onset can be insidious, progression is usually slow, and treatment is most successful with rehabilitation strategies.
            - Susan Perlman, MD
Until we better understand the causes of post-polio syndrome, we will have no curative medication. At best, we can use medication to treat the symptoms and to improve the quality of life, and we can avoid using medication that could make the symptoms worse. Certain other diseases (elevated blood cholesterol levels, high blood pressure, heart disease, and cancers) require use of medications with side effects that can exacerbate symptoms of post-polio syndrome. These should be used, but with careful monitoring of the polio survivor's functioning.
Symptomatic Medication
The three primary symptoms [of PPS] that we can treat with medication are weakness of muscle, fatigue (individual muscle and generalized) and pain, i.e., post-polio pain, overuse pain, bio-mechanical pain and bone pain ( Gawne, AC, 1995). 

Drugs to reverse muscular atrophy or to improve strength by stimulating motor nerve endings to reconnect with muscle fibers (nerve growth factors) are all still experimental. They are currently being tested for use with other motor nerve diseases. Only insulin-like growth factor type 1 (IGF-1), also known as myotrophin or somatomedin-C, has been tested in people with post-polio.
syndrome (Miller, RG, 1997) (see chart) It brought no change in strength or fatiguability but did improve recovery from fatigue after exercise.
Human Growth hormone has been given to increase a person's natural level of IGF-1 but showed little or no improvement in strength (Gupta, KI, 1994).
Another approach has been to develop and test drugs that would protect the nerve-muscle connection from the new damage in the first place (neuro-protective agents). Again, several have been studied in other diseases, but only selegiline has been tested in post-polio syndrome, bringing some improvement in symptoms but no clear stabilization of the disease (Bamford, CR, 1993). Although many people use over-the-counter antioxidant preparations of various types, these have never been formally tested to prove any ability to slow down the changes of post-polio syndrome.
Anabolic steroids, often used by body builders to improve muscle bulk and power, have been tried by polio survivors and other persons with neuromuscular diseases, but The Medical Letter on Drugs and Therapeutics reports the side effects (risk of prostate cancer in men, masculinization in women) greatly outweigh the potential benefits.

Metabolic stimulants (L-carnitine*, L-acylcarnitine, co-enzyme Q), used to improve the ability of muscle to make energy and possibly reduce fatigue and improve strength, have also been tried by polio survivors, but have been associated with rare allergic reactions and insomnia (Lehmann, C, 1994; Nibbett, J, 1996). 
* A placebo-controlled study, as yet unpublished, recently done in Germany showed no significant difference between placebo and L-carnitine.
Specific anti-fatigue drugs can act either in the brain itself (on pathways controlled by dopamine and nonadrenaline) or by improving communication at the nerve-muscle connection. These are, respectively, central and peripheral agents. Centrally acting anti-fatigue medications include amantadine [Symmetrel], bromocriptine [Parlodel], selegiline [l-deprenyl], pemoline[Cylert], ephedrine and certain antidepressants (selective serotonin re-uptake inhibitors [Prozac (fluotoxine), Seroxat (paroxetine), Zoloft, Paxil, Effexor, etc.], which may also have nonadrenaline activity). All have been tested in other fatiguing neurologic illnesses but only the first three have been studied in post-polio syndrome. Amantadine provided no reduction in fatigue (Stein, DP, 1995), but bromocriptine (Bruno, RL, 1996) and selegiline (Bamford, DR, 1993) did. Several studies have been done using pyridostigmine, [Mestinon] a peripherally-acting drug, (Trojan, DA, 19931995Seizert, BP, 1994; Trojan DA, 1997 *) that reflected variable effects on fatigue, possible mild improvement in strength in very weak muscles and notable side effects (primarily gastrointestinal).  Read about this article 
CODIGO G "14" El pasado mes de febrero de 2009 y como resultado de la reunión anual del Comité de Revisión y Actualización de la Organización Mundial de la Salud, (OMS) que tuvo lugar en Delhi, durante el mes de octubre de 2008, la Clasificación Internacional de Enfermedades, en su versión 10 (ICD-10) ha adjudicado un lugar específico al Síndrome Post-Polio (SPP) clasificándolo bajo el código "G14" y excluyéndolo del código B91 (Secuelas de poliomielitis), en el que antes ese organismo lo consideraba abarcado Más informes

Post Polio Litaff, Association A.C _APPLAC Mexico

Polio Film

Entradas populares



México Post Polio Una Vida Un Camino Una Experiencia

Post Polio LITAFF A.C.
Postpoliolitaff.- Asociación Post Polio Litaff A.C Primera Organización oficial sobre Síndrome de Post Poliomielitis En México.

Polio y Efectos Secundarios SPP
- See more at:


Salk Institute

Polio Video

Polio Lungs

Polio Reinders

March Of Dimes Polio History

Erradicación de La poliomielitis

Blog Archive

Search This Blog

No more Polio

Dr. Bruno